MX2020009049A - Expresion de proteina de superficie a neumococica (pspa). - Google Patents

Expresion de proteina de superficie a neumococica (pspa).

Info

Publication number
MX2020009049A
MX2020009049A MX2020009049A MX2020009049A MX2020009049A MX 2020009049 A MX2020009049 A MX 2020009049A MX 2020009049 A MX2020009049 A MX 2020009049A MX 2020009049 A MX2020009049 A MX 2020009049A MX 2020009049 A MX2020009049 A MX 2020009049A
Authority
MX
Mexico
Prior art keywords
pspa
surface protein
pneumococcal surface
protein expression
expression
Prior art date
Application number
MX2020009049A
Other languages
English (en)
Inventor
Ramesh Venkat Matur
Narender Dev Mantena
Mahima Datla
Rajan Sriraman
Swetha Kamireddy
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of MX2020009049A publication Critical patent/MX2020009049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a la expresión de proteína de superficie A neumocócica (PspA). La invención representa un avance en el campo de ingeniería genética y tecnología de vacunas. La invención describe vectores de expresión y células hospederas recombinantes para la expresión del péptido PspA truncado. La invención también describe composiciones de vacuna que comprenden los péptidos truncados como proteína portadora.
MX2020009049A 2018-03-01 2019-03-01 Expresion de proteina de superficie a neumococica (pspa). MX2020009049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841007814 2018-03-01
PCT/IB2019/051655 WO2019167008A1 (en) 2018-03-01 2019-03-01 Expression of pneumococcal surface protein a (pspa)

Publications (1)

Publication Number Publication Date
MX2020009049A true MX2020009049A (es) 2020-10-12

Family

ID=66440079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009049A MX2020009049A (es) 2018-03-01 2019-03-01 Expresion de proteina de superficie a neumococica (pspa).

Country Status (20)

Country Link
US (2) US11725029B2 (es)
EP (1) EP3758746A1 (es)
JP (2) JP7334176B2 (es)
KR (1) KR102774793B1 (es)
CN (1) CN112118865B (es)
AU (1) AU2019226487B2 (es)
BR (1) BR112020017431A2 (es)
CA (1) CA3091583A1 (es)
CL (1) CL2020002246A1 (es)
CU (1) CU24709B1 (es)
EA (1) EA202092065A1 (es)
IL (1) IL277023B2 (es)
MX (1) MX2020009049A (es)
MY (1) MY204760A (es)
PH (1) PH12020551357A1 (es)
SA (1) SA520420041B1 (es)
SG (1) SG11202008124XA (es)
UA (1) UA129585C2 (es)
WO (1) WO2019167008A1 (es)
ZA (1) ZA202005414B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
WO2006028063A1 (ja) 2004-09-09 2006-03-16 Research Institute Of Innovative Technology For The Earth プロモーター機能を有するｄｎａ断片
CA2729545C (en) 2008-06-25 2019-07-09 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
US20120135037A1 (en) * 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN107674118A (zh) * 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗

Also Published As

Publication number Publication date
ZA202005414B (en) 2022-02-23
JP2023154063A (ja) 2023-10-18
CL2020002246A1 (es) 2021-01-15
SG11202008124XA (en) 2020-09-29
EP3758746A1 (en) 2021-01-06
IL277023B2 (en) 2025-11-01
IL277023A (en) 2020-10-29
US20210009641A1 (en) 2021-01-14
JP2021516050A (ja) 2021-07-01
BR112020017431A2 (pt) 2021-01-19
AU2019226487A1 (en) 2020-09-10
CU24709B1 (es) 2024-06-11
IL277023B1 (en) 2025-07-01
CA3091583A1 (en) 2019-09-06
JP7334176B2 (ja) 2023-08-28
JP7645946B2 (ja) 2025-03-14
KR20200129121A (ko) 2020-11-17
EA202092065A1 (ru) 2020-11-19
SA520420041B1 (ar) 2024-03-14
PH12020551357A1 (en) 2021-08-23
CN112118865A (zh) 2020-12-22
UA129585C2 (uk) 2025-06-11
KR102774793B1 (ko) 2025-02-27
US11725029B2 (en) 2023-08-15
AU2019226487B2 (en) 2025-08-07
WO2019167008A1 (en) 2019-09-06
MY204760A (en) 2024-09-11
CN112118865B (zh) 2025-03-28
CU20200064A7 (es) 2021-04-07
US20230322871A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
BR112017014560A2 (pt) profármacos de cnp
PE20180505A1 (es) Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres
PE20181923A1 (es) Neoantigenos y metodos de su uso
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
UY37456A (es) Inmunoglobulinas y sus usos
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
PE20181156A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia genica
MX2020013579A (es) Componentes cascada y complejos cascada producidos por ingenieria.
MX2024015050A (es) L-asparaginasa modificada
PE20181275A1 (es) Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
UY40283A (es) Método para alterar una propiedad de una planta
BR112018006995A2 (pt) receptores anti-cd30 de antígeno quimérico
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
ECSP15014133A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2020010718A (es) Composiciones y metodos para el trasplante de celulas madre.